Skip to main content

Table 2 Secondary outcome measures

From: Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study

CLD

IBD

RA

• Change in model for end-stage liver disease (MELD) scores over the 24-week period.

• Complications of CLD (frequency of ascitic paracentesis, number of hospital admissions, the incidence of serious infections such a spontaneous bacterial peritonitis).

• For those who undergo LT, post-operative complications, e.g. length of admission.

• Transplant free survival time.

• Quality of life measures.

• Physical activity indices.

• Change in clinical status.

• Change in mucosal healing, as defined by Travis et al, [45], symptoms scoring including Harvey Bradshaw Index scoring and severity staging including Mayo scoring.

• Complications of IBD (number of hospital admissions, number of acute flares).

• Quality of Life measures.

• Physical activity indices.

• Change in disease activity (ACR response criteria, DAS28 response, achievement of ACR/EULAR remission criteria).

• Complications of RA (number of hospital admissions, number of acute flares)

• Quality of life measures.

• Physical activity indices.